Merck & Co. Inc.

06/21/2022 | Press release | Distributed by Public on 06/21/2022 14:40

Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence